Want to see GB:FAB full AI Analyst Report?
FAB Stock Chart & Stats
11.25 p
0.65 p(6.05%)
At close: 4:00 PM EDT
11.25 p
0.65 p(6.05%)
Day’s Range― - ―
52-Week Range9.00 p - 21.00 p
Previous CloseN/A
Volume23.22K
Average Volume (3M)429.57K
Market Cap
£13.77M
Enterprise Value14.92 p
Total Cash (Recent Filing)£1.04M
Total Debt (Recent Filing)£331.00K
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Dec 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,156,876
10 Day Avg. Volume567,950
30 Day Avg. Volume429,569
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)8.89
Price to Sales (P/S)6.83
P/FCF Ratio-12.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.10M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe 2026 revenue rebound shows renewed demand for Fusion Antibodies’ services and provides a stronger base for operating leverage. If growth persists, higher project volumes could help absorb the company’s fixed laboratory and development costs over the next several quarters.
Improved Gross MarginA materially higher gross margin indicates better economics on the work being delivered and strengthens the potential for future profitability. Maintaining this improvement would give incremental revenue greater contribution toward overhead, research capacity, and eventual operating cash generation.
Contained LeverageContained leverage gives Fusion Antibodies more financial flexibility than a heavily indebted business and limits the immediate burden of interest and principal obligations. This supports continued investment in its antibody discovery and engineering capabilities while reducing balance-sheet pressure during recovery.
Bears Say
Persistent UnprofitabilityVery large operating and net losses show that the current revenue base does not yet cover the cost of running the business. Until margins improve substantially, growth may not translate into shareholder value or internally funded expansion, leaving execution and scale-up risk elevated.
Negative Cash GenerationOngoing negative operating and free cash flow means Fusion Antibodies is consuming cash rather than funding operations from customers. Continued reliance on external funding can constrain strategic choices, increase financing risk, and make investment in future capabilities harder to sustain.
Volatile Revenue And Limited ScaleThe multi-year revenue volatility and decline from earlier levels indicate that the recent rebound has not yet established a dependable growth trajectory. Combined with persistent losses, this suggests the business remains below sustainable scale and vulnerable to uneven project demand.
Fusion Antibodies Plc News
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 9.00 p and its highest was 21.00 p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £13.77M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Dec 07, 2026 which is in 76 days.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Sep 14, 2026. The company reported -0.005 p earnings per share for the quarter.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 125,156,876 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.005 p in its last earnings report. Following the earnings report the stock price went down -21.277%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Scancell Holdings
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―